<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        75-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIVAZAC 150MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:</p><p>VIVAZAC belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten which results in an increased in blood pressure.</p><p>VIVAZAC prevents the binding of angiotensin II to these receptors, causing the blood vessels to relax and the blood pressure to lower.</p><p>VIVAZAC slows the decrease of kidney function in patients with high blood pressure and type II diabetes.</p><p>Therapeutic indications: VIVAZAC is used in adult patients to:<br />&bull;Treat high blood pressure (essential hypertension).<br />&bull;Protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take VIVAZAC if you</strong><br />&bull;Are allergic (hypersensitive) to irbesartan or any other ingredients<br />&bull;Are more than 3 months pregnant. (It is also better to avoid VIVAZAC in early pregnancy).<br />&bull;Have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p><strong>b. Take special care with VIVAZAC Tablets</strong><br />Tell your doctor if any of the following apply to you:<br />&bull;If you get excessive vomiting or diarrhea;<br />&bull;If you suffer from kidney problems;<br />&bull;If you suffer from heart problems;<br />&bull;If you receive VIVAZAC for diabetic kidney disease. In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function;<br />&bull;If you are going to have an operation (surgery) or be given anesthetics.<br />&bull;if you are taking any of the following medicines used to treat high blood pressure:<br />-An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems<br />-Aliskiren<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>You must tell your doctor if you think you are (or might become pregnant). VIVAZAC is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p><em>Children and adolescents</em><br />This medicinal product should not be used in children and adolescents because the safety and efficacy have not yet been fully established.</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your doctor may need to change your dose and/or to take other precautions:<br />You may need to have blood checks if you take:<br />&bull;Potassium supplements<br />&bull;Salt substitutes containing potassium<br />&bull;Potassium-sparing medicines (such as certain diuretics)<br />&bull;Medicines containing lithium<br />If you take certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of Irbesartan may be reduced.</p><p><strong>d. Taking VIVAZAC Tablets with food and drink:</strong><br />VIVAZAC can be taken with or without food.</p><p><strong>e. Pregnancy and breast-feeding:</strong><br /><em>Pregnancy:</em><br />You must tell your doctor if you think you are (or might become pregnant). Your doctor will normally advise you to stop taking VIVAZAC before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of VIVAZAC.</p><p>VIVAZAC is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><em>Lactation:</em><br />Tell your doctor if you are breast-feeding or about to start breastfeeding. VIVAZAC is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>f. Driving and using machines</strong><br />No studies on the effects on the ability to drive and use machines have been performed. VIVAZAC is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.</p><p><strong>g. Important information about one of the ingredients</strong><br />in VIVAZAC contains lactose. If you have been told by your doctor that you have intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take VIVAZAC exactly as your doctor has told you.<br />You should check with your doctor or pharmacist if you are not sure.</p><p><strong>Method of administration:</strong><br />VIVAZAC is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water).You can take VIVAZAC with or without food. Try to take your daily dose at about the same time each day. It is important that you continue to take VIVAZAC until your doctor tells you otherwise.</p><p><strong>Patients with high blood pressure</strong><br />The usual dose is 150 mg once a day. The dose may later be increased to 300 mg once daily depending on blood pressure response.</p><p><strong>Patients with high blood pressure and type 2 diabetes with kidney disease</strong></p><p>In patients with high blood pressure and type 2 diabetes, 300 mg (tow tablets a day) once dai-ly is the preferred maintenance dose for the treatment of associated kidney disease.</p><p><br />The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on hemodialysis, or those over the age of 75 years.<br />The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.</p><p>Use in children and adolescents<br />VIVAZAC should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.</p><p><strong>a. If you take more VIVAZAC than you should:</strong><br />If you accidentally take too many tablets, contact your doctor immediately.</p><p><strong>Signs and symptoms:</strong></p><p>Experience in adults exposed to doses of up to 900 mg/ day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose.<br />No specific information is available on the treatment of overdose with VIVAZAC.</p><p><strong>Treatment:</strong><br />The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose.</p><p>Irbesartan is not removed by hemodialysis.</p><p><strong>b. If you forget to take VIVAZAC Tablets:</strong><br />If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this product ask your doctor or pharmacist.</p><p><strong>c. If you stop taking VIVAZAC Tablets:</strong><br />Do not stop taking VIVAZAC Tablets unless your doctor tells you to. Treatment with VIVAZAC Tablets should be stopped gradually, especially if you have been taking a high dose, unless your doctor has told you otherwise. Stopping treatment suddenly may cause effects such as an increase in heart rate and high blood pressure. If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, VIVAZAC Tablets can cause side effects, although not everybody gets them. The following side effects have been reported:<br />As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localized swelling of the face, lips and/or tongue have been reported in patients taking irbesatan.<br />If you get any of these symptoms or get short of breath, stop taking VIVAZAC and contact your doctor immediately.</p><p>The frequency of the side effects listed below is defined using the following convention:</p><p><strong>Very common: at least 1 in 10 patients or more.</strong><br />If you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium<br /><strong>Common: at least 1in 100 and less than 1 in 10 patients.</strong><br />Dizziness, feeling sick vomiting, fatigue and blood tests may show raised level of an enzyme that measures the muscle and heart function (creatine kinase enzyme). In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when getting up from a lying or sitting<br />position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (hemoglobin) were&nbsp; also reported.<br /><strong>Uncommon: at least 1 in 1000and less than 1 in 100 patients.</strong><br />Heart rate increased, flushing, cough, diarrhea, indigestion heartburn, sexual dysfunction (problems with sexual performance), chest pain.<br /><strong>Undesirable effects where the frequency is not known are:</strong><br />Feeling of spinning, headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, abnormal liver function, increased blood potassium levels, impaired kidney function, and inflammation of small blood vessels mainly affecting the skin (a condition known as leukocytoclastic vasculitis). Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.</p><p>Reporting of side effects:<br />If any of the side effects gets serious or if you notice any side effects not listed in this leaflet. Please tell your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep out of the reach and sight of children.<br />-Store below 30&deg;C, protect from moisture.<br />-Do not use VIVAZAC after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />-Do not use VIVAZAC if you notice description of the visible signs of deterioration.</p><p><br />-Medicines should not be disposed of via wastewater or household waste.</p><p>Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VIVAZAC 150mg: Each film coated tablet contains Irbesartan 150 mg.<br />VIVAZAC 300mg: Each film coated tablet contains Irbesartan 300 mg.</p><p>Other ingredients are: Lactose Monohydrate, Croscarmellose Sodium, Hypromellose, Microcrystalline Cellulose, Colloidal silicon dioxide, Magnesium stearate &amp; Opadry White</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film Coated Tablets

Physical Description:
VIVAZAC 150mg: White biconvex oval shaped tablet embossed with £40 on one side and plane on the other.
VIVAZAC 300mg: White biconvex caplet shape tablet embossed with £41 on one side and plane on the other.
VIVAZAC Tablets are packed in blisters of PVC / PVDC/ Aluminum foil, in carton box with a multi folded leaflet.

Pack size: 30 F.C. Tablets; (10 F.C. Tablets /blister, 3 blisters pack).
Hospital packs are also available.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi</p><p>Riyadh, Kingdome Saudi Arabia.<br />info-ksa@mspharma.com</p><p>Manufacturer by<br />United Pharmaceutical Mfg. Co. Ltd. - Jordan for MS Pharma-Saudi.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 in Feb/2020; version number: SPM190334

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">المجموعة العلاجية:</p><p style="direction: rtl;">ينتمي فيفيزاك إلى مجموعة من الأدوية المعروفة باسم مضادات مستقبلات أنجيوتنسين الثاني. أنجيوتنسين الثاني هو عبارة عن مادة تنتج في الجسم وتربط بمستقبلات في الأوعية الدموية مما يسبب في شدها و يؤدي إلى زيادة في ضغط الدم. يمنع فيفيزاك من ارتباط الأنجيوتنسين الثاني لهذه المستقبلات، مما يسبب في استرخاء الأوعية الدموية وانخفاض ضغط الدم.</p><p style="direction: rtl;">يبطىء فيفيزاك من انخفاض وظائف الكلى في المرضى الذين يعانون من ارتفاع ضغط الدم وداء السكري من النوع الثاني.</p><p style="direction: rtl;">الاستعمالات العلاجية:</p><p style="direction: rtl;">يستعمل فيفيزاك في المرضى البالغين لـ:</p><p style="direction: rtl;">&bull;علاج ارتفاع ضغط الدم (ضغط الدم الاساسي).</p><p style="direction: rtl;">&bull;حماية الكلى في المرضى الذين يعانون من ارتفاع ضغط الدم، داء السكري من النوع الثاني وأدلة مخبرية لحدوث اختلال في وظائف الكلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>أ. لا تأخذ فيفيزاك&nbsp; إذا كنت</strong></p><p style="direction: rtl;">&bull;إذا كنت تعاني من حساسية (فرط الحساسية) لاربيسارتان أو لأي من المكونات الأخرى.</p><p style="direction: rtl;">&bull;خلال الأشهر الست الأخيرة من الحمل (من الأفضل الامتناع عن تناول فيفيزاك&nbsp; في بداية الحمل).</p><p style="direction: rtl;">&bull;تعاني من مرض السكري أو ضعف في وظائف الكلى ويتم علاجك بدواء يخفض ضغط الدم يحتوي على أليسكيرن.</p><p style="direction: rtl;"><strong>ب. الاحتياطات عند استعمال أقراص فيفيزاك&nbsp;</strong></p><p style="direction: rtl;">أخبر طبيبك إذا كان أي من الحالات التالية تنطبق عليك:</p><p style="direction: rtl;">&bull;إذا كنت تعاني من القيء المفرط أو الإسهال.</p><p style="direction: rtl;">&bull;إذا كنت تعاني من مشاكل في الكلى.</p><p style="direction: rtl;">&bull;إذا كنت تعاني من مشاكل في القلب.</p><p style="direction: rtl;">&bull;إذا كنت تتناول فيفيزاك لمرض الكلى السكري. في هذه الحالة فإن طبيبك قد يجري اختبارات دم روتينية، وخاصة لقياس مستويات البوتاسيوم في الدم في حالة ضعف وظيفة الكلى.</p><p style="direction: rtl;">&bull;إذا كنت تخطط لاجراء عملية جراحية أو التعرض للتخدير.</p><p style="direction: rtl;">&bull;إذا كنت تتناول أي من الأدوية التالية المستخدمة في علاج ضغط الدم المرتفع:</p><p style="direction: rtl;">-مثبطات الإنزيم المحول للأنجيوتنسين (على سبيل المثال إنالابريل، ليسينوبريل، راميبريل)، خاصة إذا كان لديك مشاكل في الكلى ذات صلة بمرض السكري</p><p style="direction: rtl;">-أليسكيرين</p><p style="direction: rtl;">قد يقوم طبيبك بفحص وظائف الكلى وضغط الدم ومقدار الشوارد (على سبيل المثال البوتاسيوم) في الدم على فترات منتظمة.</p><p style="direction: rtl;">يجب عليك إخبار الطبيب إذا كنت تعتقدين بأنك (أو قد تصبحين) حاملا. لا ينصح باستعمال اربيسارتان في المرحلة المبكرة من الحمل ويمكن أن يتسبب في إلحاق ضرر جسيم لطفلك بعد 3 أشهر من الحمل.</p><p style="direction: rtl;">الأطفال والمراهقين</p><p style="direction: rtl;">يجب عدم استعمال هذا الدواء في الأطفال والمراهقين لأنه لم يثبت مدى امان والفعالية الدواء بالكامل.</p><p style="direction: rtl;"><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p style="direction: rtl;">أخبر طبيبك أو الصيدلي إذا كنت تأخذ أو تناولت مؤخرا أي أدوية أخرى.</p><p style="direction: rtl;">قد يحتاج طبيبك إلى تغيير الجرعة و / أو اتخاذ احتياطات أخرى:</p><p style="direction: rtl;">قد تحتاج إلى إجراء فحوص للدم إذا كنت تتناول:</p><p style="direction: rtl;">&bull;مكملات البوتاسيوم.</p><p style="direction: rtl;">&bull;بدائل الملح التي تحتوي على البوتاسيوم،</p><p style="direction: rtl;">&bull;الأدوية المقتصدة للبوتاسيوم (مثل بعض مدرات البول)</p><p style="direction: rtl;">&bull;الأدوية التي تحتوي على الليثيوم</p><p style="direction: rtl;">قد ينخفض تأثير اربيسارتان إذا كنت تتناول بعض المسكنات، الأدوية المضادة للالتهاب اللاستيرويدية.</p><p style="direction: rtl;">د. تناول أقراص فيفيزاك مع الطعام والشراب</p><p style="direction: rtl;">يمكن تناول أقراص فيفيزاك بشكل مستقل عن وجبات الطعام.</p><p style="direction: rtl;"><strong>هـ. الحمل والرضاعة</strong></p><p style="direction: rtl;">الحمل:</p><p style="direction: rtl;">يجب أن تخبر طبيبك إذا كنت تعتقدين بأنك (أو قد تصبح) حاملا. عادة، سوف ينصحك طبيبك بالتوقف عن تناول فيفيزاك&nbsp; قبل أن تصبحي حاملا أو بأقرب وقت ممكن بعد علمك بالحمل وينصحك باستعمال دواء اخر بدلا من فيفيزاك .</p><p style="direction: rtl;">لا ينصح بتناول فيفيزاك&nbsp; في المرحلة المبكرة من الحمل ، ويجب عدم أخذه بعد 3 أشهر الاولى من الحمل، لأنها قد تسبب ضررا خطيرا لطفلك إذا ما استخدمت بعد الشهر الثالث من الحمل.</p><p style="direction: rtl;">الرضاعة الطبيعية:</p><p style="direction: rtl;">أخبر طبيبك إذا كنت ترضعين رضاعة طبيعية أو على وشك البدء في الرضاعة الطبيعية. لا ينصح باستعمال فيفيزاك في الأمهات المرضعات، وقد يختار طبيبك علاج آخر إذا كنت ترغبين في الرضاعة الطبيعية، خاصة إذا كان طفلك حديث الولادة أو ولد قبل الأوان.</p><p style="direction: rtl;"><strong>و. القيادة واستعمال الآلات</strong></p><p style="direction: rtl;">لم تجرى دراسات لمعرفة التأثير على القدرة على القيادة واستعمال الآلات. من غير المرجح أن يؤثر فيفيزاك على قدرتك على القيادة أو استعمال الآلات. ومع ذلك، قد يحدث دوخة أو تعب أحيانا أثناء علاج ارتفاع ضغط الدم. إذا واجهت مثل هذه الاعراض، يجب عليك التحدث مع طبيبك قبل محاولة القيادة أو استعمال الآلات.</p><p style="direction: rtl;"><strong>ز. معلومات مهمة عن مكون من مكونات فيفيزاك&nbsp;</strong></p><p style="direction: rtl;">يحتوي فيفيزاك على اللاكتوز. إذا قيل لك من قبل طبيبك أن لديك تعصب لبعض السكريات (مثل اللاكتوز)، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">دائما تناول أقراص فيفيزاك تماما كما أخبرك طبيبك أو الصيدلي. تحقق مع الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p style="direction: rtl;">طريقة الاعطاء:</p><p style="direction: rtl;">مخصص فيفيزاك للاستعمال عن طريق الفم. يجب بلع الأقراص مع كمية كافية من السوائل (مثل كوب واحد من الماء). يمكنك تناول فيفيزاك&nbsp; مع أو بدون الطعام. حاول تناول الجرعة اليومية الخاصة بك في نفس الوقت تقريبا كل يوم. من المهم أن تستمر في تناول فيفيزاك حتى يخبرك طبيبك خلاف ذلك.</p><p style="direction: rtl;">المرضى الذين يعانون من ارتفاع ضغط الدم:</p><p style="direction: rtl;">الجرعة الاعتيادية هي 150 ملغم تؤخذ مرة واحدة يوميا. يمكن زيادة الجرعة لاحقاً إلى 300 ملغم تؤخذ مرة واحدة يوميا اعتمادا على مدى التحكم بضغط الدم.</p><p style="direction: rtl;">المرضى الذين يعانون من ارتفاع ضغط الدم وداء السكري من النوع الثاني مع مرض الكلى:</p><p style="direction: rtl;">في المرضى الذين يعانون من ارتفاع ضغط الدم وداء السكري من النوع الثاني، يعطى 300 ملغم (قرصين يوميا) مرة واحدة يوميا كجرعة استمرارية مفضلة لعلاج أمراض الكلى المرتبطة بها.</p><p style="direction: rtl;">قد ينصح الطبيب بتناول جرعة أقل، وخاصة عند بدء العلاج في بعض المرضى مثل مرضى غسيل الكلى، أو أولئك الذين تزيد أعمارهم على 75 عاما.</p><p style="direction: rtl;">يجب التوصل للتأثير الأعظم لخافض ضغط الدم خلال 4 - 6 أسابيع بعد بداية العلاج.</p><p style="direction: rtl;">الاستعمال في الأطفال والمراهقين</p><p style="direction: rtl;">يجب عدم إعطاء فيفيزاك للأطفال دون سن 18 سنة من العمر. إذا ابتلع الطفل بعض الأقراص، اتصل بطبيبك على الفور.</p><p style="direction: rtl;"><strong>أ.إذا تناولت فيفيزاك أكثر مما يجب</strong></p><p style="direction: rtl;">إذا أخذت بطريق الخطأ العديد من الأقراص، اتصل بطبيبك فورا.</p><p style="direction: rtl;">الأعراض والعلامات:</p><p style="direction: rtl;">لم تكشف الدراسات في البالغين الذين يتناولون جرعات تصل إلى 900 ملغم يومياً لمدة 8 أسابيع أي أعراض للسمية. من المتوقع أن يكون انخفاض ضغط الدم وتسارع دقات القلب هما العرضان الأكثر احتمالا لفرط الجرعة؛ قد يحدث تباطىء في دقات القلب أيضا مع فرط الجرعة.لا يتوفرمعلومات محددة في علاج فرط الجرعة مع فيفيزاك.</p><p style="direction: rtl;">العلاج:</p><p style="direction: rtl;">يجب مراقبة المريض عن كثب، ويجب تطبيق العلاج العرضي والداعم. تشمل التدابير المقترحة تحريض التقيؤ و / أو غسل المعدة. قد يكون من المفيد استعمال الفحم المنشط في علاج فرط الجرعة. لا تتم إزالة اربيسارتان بواسطة غسيل الكلى.</p><p style="direction: rtl;"><strong>ب. إذا نسيت تناول أقراص فيفيزاك&nbsp;</strong></p><p style="direction: rtl;">إذا نسيت عن طريق الخطأ جرعتك اليومية، تناول فقط الجرعة التالية كالمعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p style="direction: rtl;">إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p style="direction: rtl;"><strong>ج. اذا توقفت عن تناول أقراص فيفيزاك&nbsp;</strong></p><p style="direction: rtl;">لا تتوقف عن تناول أقراص فيفيزاك الا إذا أخبرك الطبيب بذلك. يجب التوقف عن العلاج بأقراص فيفيزاك بشكل تدريجي، خاصة إذا كنت تتناول جرعة عالية، إلا إذا أخبرك طبيبك بخلاف ذلك. قد يؤدي توقف العلاج فجأة إلى إحداث تأثيرات مفاجئة مثل زيادة معدل ضربات القلب وارتفاع ضغط الدم. إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">وكما هو الحال في جميع الادوية، يمكن أن تسبب أقراص فيفيزاك&nbsp; آثارا جانبية، على الرغم من عدم حدوثها في الجميع. قد تم الإبلاغ عن الآثار الجانبية التالية:</p><p style="direction: rtl;">كما هو الحال مع الأدوية المماثلة، قد تم الإبلاغ عن حدوث حالات نادرة من تفاعلات حساسية الجلد (الطفح الجلدي، الشرى)، وكذلك تورم مركز في الوجه، الشفاه و / أو اللسان في المرضى الذين يتناولون فيفيزاك .</p><p style="direction: rtl;">اذا كان لديك أي من هذه الأعراض أو عانيت من ضيق في التنفس، يجب وقف تناول اربيسارتان والاتصال بطبيبك على الفور.</p><p style="direction: rtl;">تم تعريف وتيرة الآثار الجانبية المدرجة أدناه باستعمال الاتفاق التالي:</p><p style="direction: rtl;">شائعة جدا: على الاقل 1 في كل 10 أشخاص او اكثر</p><p style="direction: rtl;">إذا كنت تعاني من ارتفاع ضغط الدم وداء السكري من النوع الثاني مع مرض الكلى، قد تُـظهر اختبارات الدم زيادة في مستوى البوتاسيوم.</p><p style="direction: rtl;">شائعة: على الأقل 1 في كل 100 وأقل من 1 في 10 اشخاص.</p><p style="direction: rtl;">دوخة، الشعور بالغثيان / التقيؤ، تعب وقد تُـظهر اختبارات الدم ارتفاع في مستويات الانزيم الذي يقيس وظيفة القلب والعضلات (انزيم الكرياتين كيناز). في المرضى الذين يعانون من ارتفاع ضغط الدم وداء السكري من النوع الثاني مع مرض الكلى، قد يحدث الدوار عند الوقوف من وضعية الجلوس، وانخفاض ضغط الدم عند الوقوف من وضعية الجلوس، وآلام في المفاصل أو العضلات وقد سجل حدوث انخفاض مستويات البروتين في خلايا الدم الحمراء (الهيموجلوبين).</p><p style="direction: rtl;">غير شائعة: على الأقل 1 في كل 1000 و أقل من 1 في كل 100 شخص.</p><p style="direction: rtl;">زيادة في معدل ضربات القلب، احمرار، سعال، إسهال، عسر الهضم / حرقة، عجز جنسي (مشاكل في الأداء الجنسي)، ألم في الصدر.</p><p style="direction: rtl;">الآثار الجانبية و التي لا يعرف فيها تواتر هي:</p><p style="direction: rtl;">الشعور بالدوار، صداع، اضطراب التذوق، رنين في الآذن، تشنج العضلات، آلام في المفاصل والعضلات، وظائف غير طبيعية في الكبد، زيادة مستويات البوتاسيوم في الدم، اختلال وظائف الكلى، التهاب الأوعية الدموية الصغيرة وتصيب بشكل رئيسي الجلد (وهي حالة معروفة باسم التهاب الأوعية الدموية كاسر للكريات البيضاء). كما تم الإبلاغ عن حالات غير شائعة من اليرقان (اصفرار الجلد و / أو بياض العينين).</p><p style="direction: rtl;">للإبلاغ عن الآثار الجانبية:</p><p style="direction: rtl;">إذا أصبحت أي من الاثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">-احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p style="direction: rtl;">-يحفظ تحت &ordm;30 م، بعيداً عن الرطوبة.</p><p style="direction: rtl;">-لا تستعمل فيفيزاك بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة.Exp يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.</p><p style="direction: rtl;">-لا تستخدم فيفيزاك إذا لاحظت مواصفات علامات تدهور الرؤية.</p><p style="direction: rtl;">-لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">المادة الفعالة هي: اربيسارتان.</p><p style="direction: rtl;">-فيفيزاك 150 ملغم: كل قرص مغلف يحتوي على 150 ملغم اربيسارتان.</p><p style="direction: rtl;">-فيفيزاك 300ملغم: كل قرص مغلف يحتوي على 300 ملغم اربيسارتان.</p><p style="direction: rtl;">المكونات الأخرى هي: لاكتوز مونوهيدرات، كروسكارميلوز الصوديوم، هيبروميلوز، سيليلوز دقيق التبلور، ثاني أكسيد السيليكون الغرواني، إستارات المغنيسيوم وأوبادراي أبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            الوصف المادي: 
- أقراص فيفيزاك 150ملغم: أقراص بيضاوية ذات لون أبيض محدبة الجهتين موسومة بـ £40 على أحد الجوانب وملساء على الجانب الآخر.
- أقراص فيفيزاك 300ملغم: أقراص بيضاوية ذات لون أبيض محدبة الجهتين موسومة بـ £41 على أحد الجوانب وملساء على الجانب الآخر.
 أقراص فيفيزاك : معبأة في أشرطة من الألومنيوم و PVC/PVDC، ثم معبأة في علب كرتونية مع نشرة مطوية.
حجم العبوة: 30 قرص مغلف (10 أقراص / شريط، 3 أشرطة / العلبة).
عبوات المستشفيات متوفرة ايضا.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">إم إس فارما السعودية الرياض ، المملكة العربية السعودية .</p><p style="direction: rtl;">&nbsp;info-ksa@mspharma.com</p><p style="direction: rtl;">صنعت بواسطة :&nbsp;&nbsp;</p><p style="direction: rtl;">المتحدة للصناعات الدوائية - الأردن لصالح إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            بتاريخ فبراير/2020؛
 رقم النسخة : SPM190334

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VIVAZAC® 150mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material Name	Function	Amount (mg)/ one tablet
Irbesartan	Active material	150
Core In-active ingredients:
Lactose Monohydrate	Diluent	55.5
Crosscarmellose Sodium	Disintegrant	12.5
Hypromellose	Binder	7.5
Microcrystalline Cellulose	Diluent	20.1
Colloidal silicon dioxide	Glidant	1.9
Magnesium stearate	Lubricant	2.5
Total	250
Film coating In-active ingredients:
HPMC based coating system*	Film coating material	5.0

*Opadry White OY-L-28900.

For a full list of excipients, see section 6.1 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets

VIVAZAC® 150mg F.C. Tablets: White biconvex oval shaped tablet embossed with E40 on one side and plane on the other.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>VIVAZAC<sup>&reg;</sup> </strong>is indicated in adults for the treatment of essential hypertension.</p><p>It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Orally.</p><p><u>Posology</u></p><p>The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Irbesartan at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</p><p>In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan can be increased to 300 mg, or other antihypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Irbesartan.</p><p>In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</p><p>The demonstration of renal benefit of Irbesartan in hypertensive type 2 diabetic patients where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure.</p><p><u>Special Populations</u></p><p><em>Renal impairment</em>: no dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis.</p><p><em>Hepatic impairment</em>: no dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</p><p><em>Older people</em>: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.</p><p><em>Paediatric population</em>: the safety and efficacy of Irbesartan in children aged 0 to 18 has not been established. no recommendation on a posology can be made.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients.
•	Second and third trimesters of pregnancy.
•	The concomitant use of Irbesartan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Intravascular volume depletion</u>: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Irbesartan.</p><p><u>Reno-vascular hypertension</u>: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Irbesartan, a similar effect should be anticipated with angiotensin-II receptor antagonists.</p><p><u>Renal impairment and kidney transplantation</u>: when Irbesartan is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Irbesartan in patients with a recent kidney transplantation.</p><p><u>Hypertensive patients with type 2 diabetes and renal disease</u>: the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the patients with advanced renal disease. In particular, they appeared less favorable in women and non-white subjects</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</u></p><p><u>T</u>here is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><u>Hyperkalemia</u>: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalemia may occur during the treatment with Irbesartan, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended</p><p><u>Lithium</u>: the combination of lithium and Irbesartan is not recommended</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u>: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><u>Primary aldosteronism</u>: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Irbesartan is not recommended.</p><p><u>General</u>: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</p><p>As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population</p><p><u>Pregnancy:</u>&nbsp;Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p><u>Lactose</u>: this medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Paediatric population</u>: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diuretics and other antihypertensive agents</u>: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Irbesartan has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Irbesartan</p><p><u>Aliskiren-containing products or ACE-inhibitors</u>: dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent</p><p><u>Potassium supplements and potassium-sparing diuretics</u>: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended</p><p><u>Lithium</u>: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><u>Non-steroidal anti-inflammatory drugs</u>: when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><u>Additional information on irbesartan interactions</u>: the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u>:</p><p>The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy.</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia).</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed.</p><p><u>Breast-feeding</u>:</p><p>Because no information is available regarding the use of Irbesartan during breast-feeding, Irbesartan is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>It is unknown whether irbesartan or its metabolites are excreted in human milk.</p><p>Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk</p><p><u>Fertility</u></p><p>Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Based on its pharmacodynamic properties, irbesartan is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with hypertension, the overall incidence of adverse events did not differ. Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients. The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</p><p>In diabetic hypertensive patients with micro albuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in patients (i.e., uncommon)</p><p>The following table presents the adverse drug reactions. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria</p><p>The frequency of adverse reactions listed below is defined using the following convention:</p><p>Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Adverse reactions additionally reported from post&ndash;marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</p><table border="0" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em><u>Immune system disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>hypersensitivity reactions such as angioedema, rash, urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Metabolism and nutrition disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>hyperkalemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Nervous system disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>dizziness, orthostatic dizziness*</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>vertigo, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Ear and labyrinth disorder:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>tinnitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Cardiac disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>tachycardia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Vascular disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>orthostatic hypotension*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Respiratory, thoracic and mediastinal disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Gastrointestinal disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>nausea/vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>diarrhoea, dyspepsia/heartburn</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>dysgeusia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Hepatobiliary disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>hepatitis, abnormal liver function</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Skin and subcutaneous tissue disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>leukocytoclastic vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Musculoskeletal and connective tissue disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>musculoskeletal pain*</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Renal and urinary disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>impaired renal function including cases of renal failure in patients at risk</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Reproductive system and breast disorders:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>sexual dysfunction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>General disorders and administration site conditions:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>chest pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Investigations:</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hyperkalemia* occurred more often in diabetic patients treated with irbesartan. In diabetic hypertensive patients with micro albuminuria and normal renal function, hyperkalemia occurred in patients in the irbesartan 300 mg group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalemia occurred in patients in the irbesartan group.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Significant increases in plasma creatine kinase were commonly observed in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.</p><p>In hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in hemoglobin*, which was not clinically significant, has been observed.</p></td></tr></tbody></table><p><u>Paediatric population</u>:</p><p>In hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in headache, hypotension dizziness, and cough. In the most frequent laboratory abnormalities observed were creatinine increases and elevated CK values in child recipients.</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone : 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>-&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Irbesartan. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</strong></p><p><strong>ATC code: C09C A04.</strong></p><p><u>Mechanism of action</u>: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub>&nbsp;receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</p><p><u>Clinical efficacy</u>:</p><p><u>Hypertension</u></p><p>Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic).</p><p>Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</p><p>The blood pressure lowering effect of Irbesartan is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</p><p>The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.</p><p>The efficacy of Irbesartan is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</p><p>There is no clinically important effect on serum uric acid or urinary uric acid secretion.</p><p><u>Paediatric population</u></p><p>Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in&nbsp; hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), and 5.6 mmHg (high dose).</p><p><u>Hypertension and type 2 diabetes with renal disease</u></p><p>The &ldquo;Irbesartan Diabetic Nephropathy irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. When the individual components of the primary endpoint were analyzed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</p><p>Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented a renal benefit was not evident, although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p>Effects of Irbesartan on Micro albuminuria in Hypertensive Patients with type 2 Diabetes Mellitus: irbesartan 300 mg delays progression to overt proteinuria in patients with micro albuminuria. Examined the long-term effects (2 years) of Irbesartan on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was &le; 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normo-albuminuria (&lt; 30 mg/day) was more frequent in the Irbesartan 300 mg group.</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>No significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>Aliskiren in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints:</p><p>Cardiovascular death and stroke were both numerically more frequent in the aliskiren group and adverse events and serious adverse events of interest (hyperkalemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration, irbesartan is well absorbed: absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53 - 93 liters. Following oral or intravenous administration of&nbsp;<sup>14</sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%).&nbsp;</p><p>Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<sub>max</sub>&nbsp;values were also somewhat greater in older subjects (&ge; 65 years) than those of young subjects (18 - 40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</p><p>Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of&nbsp;<sup>14</sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of irbesartan were evaluated Results showed that C<sub>max</sub>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</p><p><u>Renal impairment</u>: in patients with renal impairment or those undergoing hemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by hemodialysis.</p><p><u>Hepatic impairment</u>: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.</p><p>Studies have not been performed in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, hemoglobin, and hematocrit). At very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</p><p>There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</p><p>Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabeled irbesartan is detected in rat and rabbit fetuses. Irbesartan is excreted in the milk of lactating rats.</p><p>Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydro ureter or subcutaneous oedema) in rat fetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate,</p><p>Crosscarmellose Sodium,</p><p>Hypromellose,</p><p>Microcrystalline Cellulose,</p><p>Colloidal silicon dioxide,</p><p>Magnesium stearate &amp;</p><p>Opadry White OY-L-28900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>VIVAZAC<sup>&reg;</sup> 150mg F.C. Tablets: </strong>are packed in blisters (Aluminum foil &amp; PVC coated PVDC) then packed in cardboard cartons with a multi-folded leaflet.</p><p>Pack size: 30 F/C Tablets; (10 F/C Tablets /blister, 3 blisters/ pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma-Saudi 
King Abdulaziz road - Alrabea District
Grand Center 1st floor – Front of Kingdom Hospital
P.O Box 47315 Riyadh, 13456 Saudi Arabia
Phone: + 966112790122 
Fax: +966112471323
E-mail: Albaraa.bahhari@mspharma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September, 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>